AI Maverick Intel Inc. (OTC: AIMV) announced Tuesday the issuance of 76.5 million common shares to HEAL Group Holdings as the initial tranche of consideration under the companies’ Right of First Refusal Agreement, advancing its proposed acquisition of HEAL Access Canada Inc. The company also disclosed that the total consideration for the transaction has been adjusted from 120 million to 100 million AIMV common shares, with both parties continuing to work toward a definitive agreement.
The issuance marks a significant step in AI Maverick Intel’s strategy to expand into the healthcare technology sector through the acquisition of HEAL Access Canada, a company that operates in the medical cannabis and patient access space. According to the press release, the Right of First Refusal Agreement was originally dated Feb. 11, 2026, and the adjustments reflect ongoing negotiations between the parties.
In addition to the acquisition progress, AI Maverick Intel noted plans to pursue an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy. An uplisting to the OTCQB would enhance the company’s visibility and liquidity, potentially attracting a wider range of institutional and retail investors. For a company focused on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries, gaining access to a more senior OTC market tier could be pivotal in supporting future growth initiatives.
The acquisition of HEAL Access Canada aligns with AI Maverick Intel’s stated mission of evaluating strategic acquisitions, partnerships, and scalable platforms designed to drive long-term shareholder value. By integrating HEAL Access Canada’s operations, the company aims to leverage AI and data analytics to improve patient access and outcomes in the healthcare sector.
Investors and industry observers should note that the transaction remains subject to the execution of a definitive agreement, and the issuance of the initial consideration shares does not guarantee the completion of the acquisition. However, the move signals tangible progress in the company’s expansion plans. The decision to reduce the total consideration from 120 million to 100 million shares may reflect a more conservative valuation or adjustments based on due diligence.
For more information on the latest news and updates relating to AIMV, visit the company’s newsroom at http://ibn.fm/AIMV. The full press release is available at https://ibn.fm/mivWz.
This development underscores the growing trend of AI-focused companies branching into specialized healthcare markets. AI Maverick Intel’s ability to successfully execute this acquisition and uplist could serve as a bellwether for similar transactions in the sector, potentially impacting how investors value companies that combine artificial intelligence with regulated industries like medical cannabis.
